Antipa Minerals Ltd (ASX:AZY) (Antipa Minerals Ltd (ASX:AZY)) has today updated the market on both its farm-in projects – the Antipa-IGO Patreson Farm-in Project and the Antipa-Newcrest Wilki Farm-in.
The Paterson Project has been particularly kind of late, with seven high-priority copper, gold and pathfinder anomalies identified. Further to this, Paterson has identified:
ANGLE plc's target price has been hiked from 195p to 215p by Berenberg, which maintained its buy rating, following yesterday’s US Food and Drug Administration (FDA) clearance of the Parsortix system.
According to the broker, the long-awaited clearance of the Parsortix system, which is used to harvest cancer cells for subsequent analysis, gives ANGLE a head start over competitors in “one of the most attractive niches.”
Caerus Mineral Resources PLC (LSE:CMRS) announced a transformational change in its strategic alliance with EV Metals Group PLC following the planned acquisition by EV Metals of the majority of Johnson Matthey PLC (LSE:JMAT)’s Battery Materials business.
Johnson Matthey said today it had agreed to sell part of its Battery Materials business to Australia’s EV Metals for £50mln in cash and will also take a minority stake in EV Metals.
S & U PLC (LSE:SUS) said the last four months have seen the specialist motor finance and property bridging lender make further steady progress.
Ahead of its annual general meeting (AGM) today, the company said group profit since the beginning of February has been ahead of budget in its Advantage Finance motor finance division and Aspen Bridging, its property bridging loans arm.
Atlantic Lithium Ltd announced an additional three drill rigs, the expansion of the drilling programme, and new drilling observations at the Ewoyaa lithium project in Ghana.
AIM-traded Atlantic, which is on track to bring West Africa's first lithium mine into production, yesterday confirmed it had been approached by Ghana’s Minerals Income Investment Fund about a potential investment.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF)’s chief financial officer has said he plans to leave the company after six years to pursue non-executive roles.
Nick Wykeman will leave in six months, giving the business time to recruit a successor.
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it had been granted US patents protecting two key assets – POLB 001, a potential flu treatment, and POLB 002, a nasal spray for virus infections.
The company said it was working with its advisors to broaden and expand the patent families for both early-stage drug candidates.
Sovereign Metals Ltd (ASX:SVM, AIM:SVML) has established an environmental, social and governance (ESG) framework to guide and advance the company’s corporate social responsibility efforts in Malawi, home to its flagship Kasiya rutile deposit.
Sovereign is undertaking several development initiatives to assist Malawi and its local communities, looking to become an industry leader in its corporate social responsibility to the nation through its ESG framework.
Contract research specialist Open Orphan PLC (AIM:ORPH, OTC:OPORF) said that Liberum has concluded its due diligence on the company after being appointed its nominated advisor and joint broker.
Union Jack Oil PLC (AIM:UJO) announced that a loan made to partner Egdon Resources has been paid in full.
Reabold Resources PLC (AIM:RBD) confirmed it has now completed the equity exchange in its agreement with Daybreak Oil and Gas, which secures the company’s place in the California oil venture. As a result, Reabold now holds 42% of Daybreak’s share capital.
Destiny Pharma PLC (AIM:DEST) announced the appointment of three non-executive directors – James Stearns (a chief investment officer of China Medical System Holdings), Aled Williams (chief executive of Enthera Pharmaceuticals), and experienced life science sector advisor Nigel Brooksby.